
浏览全部资源
扫码关注微信
1.中国中医科学院 西苑医院 老年医学研究所,北京 100091
2.中国中医科学院 西苑医院 血液病研究所,北京 100091
丁小燕,在读硕士,从事老年相关疾病的防治研究,E-mail:1198949357@qq.com
周庆兵,副主任医师,博士,从事中医药防治老年相关疾病的机制研究,E-mail:zhouqingbing0910@163.com
收稿日期:2022-01-26,
网络出版日期:2022-03-09,
纸质出版日期:2022-05-05
移动端阅览
丁小燕,王洪志,张颖等.雄黄主要成分二硫化二砷对骨髓增生异常综合征SKM-1细胞的甲基化作用效应[J].中国实验方剂学杂志,2022,28(09):66-71.
DING Xiao-yan,WANG Hong-zhi,ZHANG Ying,et al.Effect of Main Component of Realgar Arsenic Disulfide (As2S2) on DNA Methylation of SKM-1 Cells with Myelodysplastic Syndrome[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(09):66-71.
丁小燕,王洪志,张颖等.雄黄主要成分二硫化二砷对骨髓增生异常综合征SKM-1细胞的甲基化作用效应[J].中国实验方剂学杂志,2022,28(09):66-71. DOI: 10.13422/j.cnki.syfjx.202201002.
DING Xiao-yan,WANG Hong-zhi,ZHANG Ying,et al.Effect of Main Component of Realgar Arsenic Disulfide (As2S2) on DNA Methylation of SKM-1 Cells with Myelodysplastic Syndrome[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(09):66-71. DOI: 10.13422/j.cnki.syfjx.202201002.
目的
2
从DNA甲基化角度探讨雄黄主要成分二硫化二砷(As
2
S
2
)对骨髓增生异常综合征细胞株SKM-1细胞的效应机制。
方法
2
细胞增殖与活性检测(CCK-8)试剂盒检测As
2
S
2
(0、1、2、4、8、16 μmol·L
-1
)对SKM-1细胞的抑制作用;碘化丙啶(PI)染色法检测As
2
S
2
(0、1、2、4 μmol·L
-1
)对SKM-1细胞周期的影响;运用人甲基化850K芯片在全基因组范围内观察As
2
S
2
(0、4 μmol·L
-1
)对SKM-1细胞的甲基化效应并进行京都基因与基因组百科全书(KEGG)与基因本体(GO)分析;根据芯片数据,选取抑癌基因TUSC3,采用实时荧光定量聚合酶链式反应(Real-time PCR)与蛋白免疫印迹法(Western blot)技术观察As
2
S
2
(0、1、2、4 μmol·L
-1
)对TUSC3 mRNA与蛋白的表达作用。
结果
2
与空白组比较,As
2
S
2
对SKM-1细胞具有显著的抑制作用;增加G
0
/G
1
期细胞比例,降低S期细胞比例(
P
<
0.05);850K芯片显示,4 μmol·L
-1
As
2
S
2
能显著引起SKM-1细胞基因组的甲基化变化,共有12 710个差异甲基化基因(高甲基化与低甲基化基因各占50%),GO与KEGG数据库分析显示,差异甲基化基因涉及嘌呤代谢,自然杀伤细胞介导的增殖抑制作用,内吞作用,趋化因子信号通路,核泛素连接酶复合体等功能与通路;在下游基因表达方面,Real-time PCR与Western blot显示,与空白组比较,As
2
S
2
明显升高抑癌基因TUSC3的表达(
P
<
0.05)。
结论
2
雄黄主要成分As
2
S
2
对MDS细胞株SKM-1细胞具有显著的甲基化调控效应,并可能通过增加抑癌基因TUSC3的表达实现治疗效应。
Objective
2
To explore the effects of the main component of Realgar arsenic disulfide (As
2
S
2
) on DNA methylation of SKM-1 cells with myelodysplastic syndrome.
Method
2
Cell Counting Kit-8 (CCK-8) was used to detect the inhibitory effect of As
2
S
2
(0, 1, 2, 4, 8, 16 μmol·L
-1
)on SKM-1 cells. Propidium iodide (PI) staining was applied to detect the effect of As
2
S
2
(0, 1, 2, 4 μmol·L
-1
)on the SKM-1 cell cycle. The effect of As
2
S
2
(0, 4 μmol·L
-1
) on the methylation of SKM-1 cells on a genome-wide scale was observed by using Human Methylation 850K BeadChip, followed by Kyoto Encyclopedia of Genes and Genomes (KEGG) and gene ontology (GO) analyses. According to the microarray data, the antioncogene TUSC3 was selected, and real-time quantitative polymerase chain reaction (Real-time PCR) and Western blot were adopted to investigate the effect of As
2
S
2
(0, 1, 2, 4 μmol·L
-1
) on the mRNA and protein expression of TUSC3, respectively.
Result
2
Compared with the conditions in the blank group, As
2
S
2
inhibited SKM-1 cells, increased the proportion of cells in the G
0
/G
1
phase, and decreased the proportion of cells in the S phase(
P
<
0.05). The 850K microarray showed that 4 μmol·L
-1
As
2
S
2
could significantly induce DNA methylation in SKM-1 cells, with 12 710 differentially methylated genes involved (50% hypermethylated and 50% hypomethylated genes). KEGG and GO analyses showed that differentially methylated genes were involved in many important biological functions and signaling pathways, including purine metabolism, natural killer cell-mediated cytotoxicity, endocytosis, chemokine signaling pathway, and nuclear ubiquitin ligase complex. In terms of downstream gene expression, Real-time PCR and Western blot showed that As
2
S
2
increased the expression of TUSC3, as compared with the conditions in the blank group (
P
<
0.05).
Conclusion
2
As
2
S
2
, the main component of Realgar, has a significant regulatory effect on the methylation of SKM-1 cells, which is presumedly achieved by increasing the expression of TUSC3.
CAZZOLA M . Myelodysplastic Syndromes [J]. N Engl J Med , 2020 , 383 ( 14 ): 1358 - 1374 .
MA X . Epidemiology of myelodysplastic syndromes [J]. Am J Med , 2012 , 125 ( 7 Suppl ): S2 - S5 .
BLECUA P , MARTINEZ-VERBO L , ESTELLER M . The DNA methylation landscape of hematological malignancies: An update [J]. Mol Oncol , 2020 , 14 ( 8 ): 1616 - 1639 .
BENETATOS L , VARTHOLOMATOS G . Enhancer DNA methylation in acute myeloid leukemia and myelodysplastic syndromes [J]. Cell Mol Life Sci , 2018 , 75 ( 11 ): 1999 - 2009 .
BOND D R , LEE H J , ENJETI A K . Unravelling the epigenome of myelodysplastic syndrome: Diagnosis, prognosis, and response to therapy [J]. Cancers (Basel) , 2020 , 12 ( 11 ): 3128 .
陈信义 , 麻柔 , 李冬云 . 规范常见血液病中医病名建议 [J]. 中国中西医结合杂志 , 2009 , 29 ( 11 ): 1040 - 1041 .
周庆兵 , 王洪志 , 王德秀 , 等 . 以雄黄为主方案治疗骨髓增生异常综合征伴多系病态造血患者的远期疗效 [J]. 世界中医药 , 2019 , 14 ( 10 ): 2787 - 2789 .
NAKAGAWA T , MATOZAKI S . The SKM-1 leukemic cell line established from a patient with progression to myelomonocytic leukemia in myelodysplastic syndrome (MDS)-contribution to better understanding of MDS [J]. Leuk Lymphoma , 1995 , 17 ( 3/4 ): 335 - 339 .
中华医学会血液学分会 . 骨髓增生异常综合征中国诊断与治疗指南(2019年版) [J]. 中华血液学杂志 , 2019 , 40 ( 2 ): 89 - 97 .
FENAUX P , HAASE D , SANTINI V , et al . Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J]. Ann Oncol , 2021 , 32 ( 2 ): 142 - 156 .
MOZESSOHN L , CHEUNG M C , FALLAHPOUR S , et al . Azacitidine in the 'real-world': An evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada [J]. Br J Haematol , 2018 , 181 ( 6 ): 803 - 815 .
麻柔 . 骨髓增生异常综合征中西医结合诊疗优势 [J]. 中国中西医结合杂志 , 2019 , 39 ( 1 ): 21 - 22 .
周庆兵 , 王洪志 , 王德秀 , 等 . 以雄黄为主方案治疗骨髓增生异常综合征伴多系病态造血患者的远期疗效 [J]. 世界中医药 , 2019 , 14 ( 10 ): 2787 - 2789 .
ZHOU Q B , YANG X H , WANG H Z , et al . Effect of Qinghuang powder combined with Bupi Yishen decoction in treating patients with refractory cytopenia with multilineage dysplasia through regulating DNA methylation [J]. Chin J Integr Med , 2019 , 25 ( 5 ): 354 - 359 .
ZHOU Q B , ZHU Q Z , WANG H Z , et al . Traditional Chinese medicine containing arsenic treated MDS patients effectively through regulating aberrant hypomethylation [J]. Evid Based Complement Alternat Med , 2020 , 2020 : 7469809 .
WANG D X , XU Y G , DU Y , et al . Arsenic concentration in peripheral blood is correlated with efficacy of a traditional Chinese medicine regimen containing realgar for the treatment of myelodysplastic syndrome [J]. J Tradit Chin Med , 2021 , 41 ( 4 ): 630 - 635 .
QUESNEL B , GUILLERM G , VEREECQUE R , et al . Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression [J]. Blood , 1998 , 91 ( 8 ): 2985 - 2990 .
VOSO M T , SCARDOCCI A , GUIDI F , et al . Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes [J]. Blood , 2004 , 103 ( 2 ): 698 - 700 .
WANG H , WANG X Q , XU X P , et al . ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome [J]. Leuk Res , 2010 , 34 ( 5 ): 598 - 604 .
康慧媛 , 王新荣 , 高丽 , 等 . ZO-1基因甲基化在MDS进展中的意义 [J]. 中国实验血液学杂志 , 2015 , 23 ( 3 ): 746 - 749 .
XU Z J , TANG C Y , ZHOU J D , et al . SOX7 methylation is an independent prognostic factor in myelodysplastic syndromes [J]. Pathol Res Pract , 2019 , 215 ( 2 ): 322 - 328 .
PAPAGGELI P C , KORTSARIS A C , MATSOUKA P T . Aberrant methylation of c-myc and c-fos protooncogenes and p53 tumor suppressor gene in myelodysplastic syndromes and acute non-lymphocytic leukemia [J]. J BUON , 2003 , 8 ( 4 ): 341 - 350 .
QIAN J , ZHU Z H , LIN J , et al . Hypomethylation of PRAME promoter is associated with poor prognosis in myelodysplastic syndrome [J]. Br J Haematol , 2011 , 154 ( 1 ): 153 - 155 .
ZHANG Y Y , ZHOU J D , YANG D Q , et al . Intragenic hypomethylation of DNMT3A in patients with myelodysplastic syndrome [J]. Clin Chem Lab Med , 2018 , 56 ( 3 ): 485 - 491 .
LIN J , QIAN J , YAO D M , et al . Aberrant hypomethylation of SALL4 gene in patients with myelodysplastic syndrome [J]. Leuk Res , 2013 , 37 ( 1 ): 71 - 75 .
WU D H , YAO D M , YANG L , et al . Hypomethylation of let-7a-3 is associated with poor prognosis in myelodysplastic syndrome [J]. Leuk Lymphoma , 2017 , 58 ( 1 ): 96 - 103 .
周晓晗 , 顾页 , 林洁 . TUSC3基因与人类癌症相关的研究进展 [J]. 转化医学电子杂志 , 2017 , 4 ( 6 ): 60 - 63 .
盛须仁 , 邢松歌 , 葛勇胜 , 等 . TUSC3基因在肝细胞癌中的表达及其临床意义 [J]. 中国普通外科杂志 , 2018 , 27 ( 1 ): 75 - 80 .
WANG S , ZHU W . Tumour suppressor candidate 3 inhibits biological function and increases endoplasmic reticulum stress of melanoma cells WM451 by regulating AKT/GSK3- β / β -catenin pathway [J]. Cell Biochem Funct , 2020 , 38 ( 5 ): 604 - 612 .
JIANG Y L , OKEEFE C , DUNBAR A , et al . High throughput methylation arrays allow for identification of complex methylation patterns in MDS [J]. Blood , 2007 , 110 ( 11 ): 2437 .
0
浏览量
19
下载量
4
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621